Overview

Safety, Tolerability and Pharmacokinetics Study of LY03005

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of escalating single oral doses of LY03005 in healthy subjects and to characterize the pharmacokinetics (PK) of escalating single oral doses of LY03005.
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Treatments:
Desvenlafaxine Succinate